摘要
目的:探讨LGT不同表达对结直肠腺癌患者手术后应用FOLFOX方案巩固治疗后远期生存的影响。方法:选取2006年1月-2009年1月首次入院并行手术治疗的结直肠腺癌患者55例,手术前行SELDI检测,留取指纹图。术后给予标准FOLFOX方案巩固化疗4～6周期。随访至2011年8月。观察2010年至今,不同年龄、性别,LGT表达与否条件下,无疾病进展生存期和中位生存期两组的差异。结果:年龄以65岁分组,两者在无疾病进展生存期和中位生存期上比较差异均无统计学意义(7.85:6.50,P=0.770;15.75:13.00,P=0.517)。按性别分组,男女在无疾病进展生存期和中位生存期上比较差异均无统计学意义(8.50:4.95,P=0.152;17.00:10.00,P=0.203)。LGT阳性者,无疾病进展中位生存期为2.8个月,LGT阴性者,无疾病进展中位生存期为10个月,差异有统计学意义(P=0.000)。LGT阳性者,中位生存期为5.85个月,LGT阴性者,中位生存期为18.5个月,差异有统计学意义(P=0.000)。结论:手术前LGT表达组无疾病进展及中位生存期远低于LGT阴性组。建议手术前如LGT为阳性表达,首先控制LGT,待LGT表达正常后再行手术,以确保治疗后效果。
Objective： To study the different expression of LGT and Long-term survival of FOLFOX chemotherapy after colorectal cancer surgery. Method： Choose 55 patients use surgical treatment of parallel colorectal, between January 2006 to January 2009.All the patient detect SELDI to get the map of fingerprint , use four to six cycles of FOLFOX chemotherapy, follow-up to August 2011. A different age, gender, LGT express or not, under the conditions of disease progression of survival and without a median of two groups of the differences. Result：In the absence of survival and disease progression median survival were no significant difference （7.85, 6.50, P=0.770;15.75：13.00, P=0.517）between ≥ 65 years old group and〈 65 years old group;There is no significant difference among the men and women group （8.50, 4.95, P=2.057;17.00：10.00, P=l.622）.No disease progress for a median is 2.8 months in LGT positive patient, 10 months in LGT negative patient（P=O.OOO）.Progress for a median is 5.85 months in LGT positive patient, 18.5 months in LGT negative patient（P=0.000）.Conclusion：Both the no disease progress for a median and progress for a median in LGT positive group is far lower than the LGT negative group.Before the operation such as LGT positive for express, first control LGT, LGT expression to normal after poste ooeration, to ensure that the treatment effect.
出处
《中国医学创新》
CAS
2012年第23期6-8,共3页
Medical Innovation of China
